Acting as chief medical adviser to US President Joe Biden, Dr. Anthony Fauci’s statement came weeks before the U.S. Drug and Food Administration (FDA) planned to grant emergency use approval, raising concerns about the vaccine previously alleged to cause blood clotting.
“WE CALL ASTRAZENECA TO EXPLAIN CURRENT DATA “
In the statement made by the institution, the following expressions were used:
“The Data Security Monitoring Board (DSMB), an independent committee that oversees the research, expressed concern AstraZeneca may have included out-of-date information in the event data. “We invite the company to work with DSMB to review the event data and make sure that the most accurate and up-to-date information is made public as soon as possible.”
No statement has yet been made from AstraZeneca on the subject.
In the US, however, authorization and guidelines for the use of work will be determined after a thorough review of the data by independent advisory committees.
AFFORDABLE COST AND STORAGE CONDITIONS MAKE IT ATTRACTIVE
AstraZeneca and the University of Oxford were seen as a milestone in the fight against the Covid-19 pandemic when they joined the global vaccine race last year, but the dosing regimen and its possible side effects have remained questionable since their clinical trials were announced at the end of last year. However, the vaccine’s high cost and ease of storage made it attractive for many countries.
Now, more than a dozen European countries have discontinued use of the vaccine earlier this month after reports of a rare blood clotting disorder in a very small number of people. Germany and France continued to vaccinate their population after the European Medicines Agent (EMA) said last week the Oxford / AstraZeneca vaccine was safe, but a poll on Monday showed that Europeans remain skeptical about the vaccine’s safety.
HOW DOES THE CORONA VIRUS AFFECT THE BRAIN?